期刊文献+

Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application

下载PDF
导出
摘要 In Korea and China,ilaprazole is a widely used proton pump inhibitor in the treatment of gastric ulcers.In this study,a specific and sensitive LC-MS/MS method has been developed and validated for the quantification of ilaprazole enantiomers in the rat plasma,using R-lansoprazole as the internal standard.The enantioseparation was achieved on a CHIRALPAK AS-RH column(4.6 mm×150 mm,i.d.5 mm),with a mobile phase composed of 10 m M ammonium acetate aqueous solution and acetonitrile(60:40,V/V),at a flow-rate of 0.5 m L/min.The method was validated over the concentration range of 0.5 e300 ng/m L for both,R-and S-ilaprazole.The lower limit of quantification was 0.5 ng/m L for both enantiomers.The relative standard deviation(RSD)of intra-and inter-day precision of R-ilaprazole and S-ilaprazole was less than 10.9%,and the relative error accuracy(RE)ranged fromà0.5%e2.0%.Finally,the method was successfully evaluated in rats in a stereoselective pharmacokinetic study of the ilaprazole racemate.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2020年第6期617-623,共7页 药物分析学报(英文版)
基金 the National Key Research and Development Program of China(2017YFC0908600) the National Natural Science Foundation of China(81773817) the National Key R&D Program of China(No.2017YFE0102200) the Fundamental Research Funds for the Central Universities(2017XZZX011-04)。
  • 相关文献

参考文献5

二级参考文献21

  • 1Kim El, Lee RK, Lee SM, Kim DY. General pharmacology of IY-81149, a new proton pump inhibitor. Arzneimittelforschung 2001; 51: 51-9.
  • 2Periclou AP, Goldwater R, Lee SM, Park DW, Kim DY, Cho KD, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 2000; 68: 304-11.
  • 3Myung SW, Min HK, Jin C, Kim M, Lee SM, Chung G J, et al. Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Arch Pharm Res 1999; 22: 189-93.
  • 4Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 2008; 39: 60-7.
  • 5Taylor PJ. Matrix effects: the Achilles heel of quantitative high- performance liquid chromatography-electrospray-tandem mass spectrometry. Clin Biochem 2005; 38: 328-34.
  • 6Karnes HT, March C. Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis. Pharm Res 1993; 10: 1420-6.
  • 7Food and Drug Administration. Guidance for Industry on Bioanalytical Method Validation. Fed Regist 2001; 66: 28526-7.
  • 8Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray I J, et al. Bioanalytical method validation -- a revisit with a decade of progress. Pharm Res 2000: 17: 1551-7.
  • 9Alberto Pilotto,Marilisa Franceschi,Stefania Maggi,Filomena Addante,Daniele Sancarlo.Optimal Management of Peptic Ulcer Disease in the Elderly[J]. Drugs & Aging . 2010 (7)
  • 10James YW Lau,Alan Barkun,Dai-ming Fan,Ernst J Kuipers,Yun-sheng Yang,Francis KL Chan.Challenges in the management of acute peptic ulcer bleeding[J].The Lancet.2013(9882)

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部